Supplementary Figure 5: Treatment with a TRPV1 antagonist reduces colitis severity in Il10–/– mice.
From: The ion channel TRPV1 regulates the activation and proinflammatory properties of CD4+ T cells
(a) Wasting disease in Il10–/– treated daily with the TRPV1 antagonist SB366791 (3 mg/kg, i.p) or with its vehicle (VEH) starting 3 days prior and daily during the 14 days of colitis induction by piroxicam (PXC). (b) Microcopy of colon sections from mice as in a, stained with hematoxylin and eosin. Scale bar, 1 mm (main images; 20× objective) or 100 μm (insets; 1× objective). (c) Colitis scores of the mice in a. (d) Enzyme-linked immunosorbent assay (ELISA) of IFN-γ and IL-17A production by spleen (SP) CD4+ T cells recovered from mice as in a, and restimulated for 24 h with anti-CD3 (10 μg/mL plate-bound) plus anti-CD28 (1 μg/mL soluble). (mean ± s.e.m. (n = 7-8 mice/group)). NS, not significant; **P <0.01 (two-tailed Student t-test). Data are representative of two independent experiments.
